Overview
This legislation fundamentally restructures how pharmacy benefits managers (PBMs) are compensated for administering and managing prescription drug benefits in New Jersey. The bill amends existing PBM regulation under P.L.2023, c.107 to mandate that all PBM compensation take the form of a 'bona fide service fee' — a flat dollar amount tied to the fair market value of actual, itemized services performed. The core objective is to sever the longstanding practice of PBM compensation being tied to drug prices, rebates, formulary placement decisions, or other volume-based incentives that critics argue create conflicts of interest and inflate drug costs for consumers and health plans. By requiring compensation to reflect genuine service value rather than drug pricing dynamics, the bill aims to increase transparency, reduce hidden financial incentives, and ensure that carrier loss ratio calculations accurately reflect true benefit costs versus administrative expenses.
Key Points
- Mandates flat-fee compensation for PBMs, eliminating price-contingent payment structures
- Targets conflicts of interest arising from rebate-based and volume-based PBM compensation
- Redefines how PBM compensation is treated in carrier loss ratio and rate filing calculations
- Applies to all contracts entered into, renewed, modified, or amended on or after the effective date
Legal References
- P.L.2023, c.107 (C.17B:27F-3.4)
Core Provisions
The bill's central mandate, established at §1.e.(1), requires that any compensation paid to a PBM or its affiliates for administering and managing prescription drug benefits must constitute a bona fide service fee. Under §1.e.(2), this fee is defined as a flat dollar amount that reflects the fair market value of a bona fide, itemized service actually performed on behalf of a purchaser. The definition explicitly prohibits the fee from being directly or indirectly based on or contingent upon drug pricing benchmarks such as wholesale acquisition cost or average wholesale price, the amount of discounts, rebates, or other remuneration associated with dispensed drugs, formulary placement decisions, or the volume or value of referrals or business generated between the PBM and purchaser. The Commissioner of Banking and Insurance retains authority to designate additional prohibited methodologies. Equally significant are the loss ratio provisions at §1.a, which recharacterize PBM compensation for regulatory accounting purposes. PBM compensation is explicitly excluded from classification as either an administrative cost or a benefit under a health benefits plan when calculating a carrier's anticipated loss ratio or any loss ratio used in medical loss ratio or rate filings. Carriers are further required under §1.a to claim only the amounts actually paid by the PBM to a pharmacy or pharmacist as incurred claims, preventing carriers from inflating incurred claim figures to include PBM markups or spread pricing. The bill takes effect on the first day of the fourth month following enactment and applies prospectively to contracts entered into, renewed, modified, or amended on or after that date.
Key Points
- PBM compensation must be a flat dollar amount reflecting fair market value of actual services performed [§1.e.(2)]
- Prohibited compensation bases include drug prices, rebate amounts, formulary placement, and referral volumes [§1.e.(2)(a)-(c)]
- PBM compensation excluded from both administrative cost and benefit classifications in loss ratio calculations [§1.a.(1)-(2)]
- Carriers may only count amounts paid by PBMs to pharmacies as incurred claims [§1.a]
- Commissioner may designate additional prohibited compensation methodologies [§1.e.(2)(d)]
Legal References
- P.L.2023, c.107, §9 (C.17B:27F-3.4)
- N.J.S.A. Title 17B (Insurance)
Implementation
The Commissioner of Banking and Insurance bears primary responsibility for implementing and enforcing this legislation. The Commissioner is authorized under §2 to take anticipatory administrative action prior to the effective date, enabling the department to issue guidance, promulgate rules, and establish compliance frameworks before the law takes effect. This anticipatory authority is critical given the complexity of restructuring existing PBM contractual arrangements across the market. Carriers bear direct compliance obligations, including a documentation requirement under §1.d that obligates them to provide the department with any records requested relating to PBM compensation. This documentation mandate serves as the primary enforcement mechanism, giving regulators visibility into PBM compensation structures that have historically been opaque. The bill does not establish a dedicated funding mechanism or appropriation, relying instead on the existing regulatory infrastructure of the Department of Banking and Insurance. Compliance is enforced through the department's existing insurance regulatory authority, which includes examination powers, market conduct oversight, and the ability to take action against carriers that fail to meet the new requirements. The prospective application of the law to contracts entered into, renewed, modified, or amended on or after the effective date provides a natural compliance transition as existing contracts come up for renewal.
Legal References
- P.L.2023, c.107 (C.17B:27F-3.4)
- N.J.A.C. Title 11 (Department of Banking and Insurance regulations)
Impact
The primary beneficiaries of this legislation are health insurance purchasers — including employers, unions, and government entities — and ultimately covered persons who bear the cost of prescription drug benefits through premiums and cost-sharing. By eliminating spread pricing and rebate-contingent compensation, the bill is designed to ensure that savings from drug discounts and rebates flow to purchasers and plan members rather than being retained by PBMs. The loss ratio provisions have direct financial implications for carriers: by excluding PBM compensation from both administrative cost and benefit categories and limiting incurred claims to amounts actually paid to pharmacies, the bill prevents carriers from using inflated PBM-related figures to justify premium increases or satisfy medical loss ratio requirements under favorable accounting treatments. The administrative burden on carriers is meaningful, as they must restructure their PBM contracts, revise their loss ratio reporting methodologies, and maintain documentation sufficient to satisfy department requests. PBMs face the most significant operational impact, as the flat-fee model eliminates revenue streams derived from spread pricing, rebate retention, and formulary management fees tied to drug volumes. The expected outcome is greater price transparency in the prescription drug supply chain and more accurate reflection of true drug benefit costs in insurance rate filings. No sunset provision is included, making this a permanent structural change to PBM regulation in New Jersey.
Key Points
- Health plan purchasers and covered persons benefit from elimination of hidden PBM revenue extraction
- Carriers must revise loss ratio reporting to exclude PBM compensation from administrative and benefit categories
- PBMs lose spread pricing and rebate-contingent revenue streams
- No sunset provision — permanent regulatory change
- No dedicated appropriation; implementation relies on existing departmental resources
Legal Framework
The bill operates as an amendment to P.L.2023, c.107 (C.17B:27F-3.4), which established New Jersey's existing PBM regulatory framework. It is grounded in New Jersey's broad authority to regulate the business of insurance under Title 17B of the New Jersey Statutes, which grants the Legislature and the Commissioner of Banking and Insurance extensive power to govern the conduct of carriers, intermediaries, and service providers operating in the state's health insurance market. The bill does not raise federal preemption concerns with respect to fully insured health plans, as state insurance regulation of this nature is expressly preserved under the McCarran-Ferguson Act. However, the bill's application to self-funded ERISA plans administered by PBMs may be limited, as ERISA generally preempts state laws that relate to employee benefit plans, a distinction the bill does not explicitly address. The Commissioner's authority to designate additional prohibited compensation methodologies under §1.e.(2)(d) constitutes a delegation of legislative power to the executive branch, which is permissible under New Jersey administrative law provided adequate standards are established. The documentation requirement under §1.d is consistent with the department's existing examination and market conduct authority. The loss ratio provisions interact directly with the Affordable Care Act's medical loss ratio requirements and New Jersey's own rate filing regulations, requiring coordination between state and federal accounting standards.
Legal References
- P.L.2023, c.107 (C.17B:27F-3.4)
- N.J.S.A. Title 17B (Insurance Code)
- Employee Retirement Income Security Act of 1974 (ERISA), 29 U.S.C. § 1001 et seq.
- McCarran-Ferguson Act, 15 U.S.C. § 1011 et seq.
- Affordable Care Act, 42 U.S.C. § 18001 et seq. (medical loss ratio provisions)
- N.J.A.C. Title 11 (Department of Banking and Insurance)
Critical Issues
The most significant implementation challenge is the determination of 'fair market value' for PBM services. The bill requires that bona fide service fees reflect fair market value for itemized services actually performed, but provides no methodology or benchmark for making this determination. Without regulatory guidance, disputes between carriers, PBMs, and the department over appropriate fee levels are likely. The Commissioner's authority to issue rules in advance of the effective date partially addresses this gap, but the absence of statutory standards creates regulatory uncertainty. The ERISA preemption issue presents a substantial limitation on the bill's reach. A significant portion of prescription drug benefits in New Jersey are administered through self-funded employer plans governed by ERISA, which generally preempts state laws that relate to employee benefit plans. To the extent the bill purports to regulate PBM compensation arrangements for self-funded plans, it may be subject to preemption challenges, effectively limiting its application to fully insured markets and leaving a large segment of the PBM industry unaffected. PBMs and their industry representatives are likely to argue that the flat-fee model eliminates financial incentives for PBMs to negotiate aggressive drug discounts and rebates, potentially increasing net drug costs for health plans. This is a substantive policy counterargument: if PBM compensation is decoupled from rebate performance, PBMs may have reduced motivation to secure favorable pricing from manufacturers. Additionally, the reclassification of PBM compensation in loss ratio calculations could create unintended distortions in rate filings, as carriers adjust to new accounting requirements that may not align cleanly with existing federal MLR reporting frameworks. The prospective-only application, while legally sound, means the full impact of the reform will be delayed as existing multi-year PBM contracts work through their natural renewal cycles.
Key Points
- No statutory methodology for determining 'fair market value' of PBM services creates regulatory uncertainty
- ERISA preemption likely limits application to fully insured plans, excluding self-funded employer plans
- Flat-fee model may reduce PBM incentives to negotiate drug manufacturer rebates
- Loss ratio reclassification may create misalignment with federal ACA medical loss ratio reporting requirements
- Prospective application delays full market impact pending contract renewals
- Enforcement depends entirely on carrier documentation compliance with no direct PBM audit authority specified
Legal References
- ERISA, 29 U.S.C. § 1144 (preemption provision)
- 42 U.S.C. § 300gg-18 (ACA medical loss ratio requirements)
- P.L.2023, c.107 (C.17B:27F-3.4)